Laboratory Tests for Bone Health Assessment
The essential laboratory tests for evaluating bone health include a complete blood count, comprehensive metabolic panel, 25-hydroxyvitamin D, intact parathyroid hormone (PTH), phosphate, and 24-hour urine collection for calcium, sodium, and creatinine 1.
Core Laboratory Panel
The AACE/ACE 2020 guidelines establish a foundational laboratory workup that should be performed in all patients being evaluated for osteoporosis 1. This approach is justified because simple laboratory tests provide useful information in 40-85% of women without obvious clinical evidence of secondary osteoporosis, identifying treatable causes that contribute to bone loss.
Primary Tests (All Patients)
- Complete blood count - screens for hematologic disorders and malignancy
- Comprehensive metabolic panel - evaluates calcium, kidney function, liver function, and alkaline phosphatase
- 25-hydroxyvitamin D [25(OH)D] - identifies vitamin D deficiency, a correctable cause of bone loss
- Intact parathyroid hormone (PTH) - detects primary hyperparathyroidism
- Phosphate - helps identify metabolic bone disease
- 24-hour urine collection for calcium, sodium, and creatinine - identifies hypercalciuria and assesses dietary intake
Critical timing consideration: The 24-hour urine calcium must be collected after the patient is vitamin D replete and has maintained adequate calcium intake (1,000-1,200 mg/day) for at least 2 weeks 1.
Conditional Tests (Based on Clinical Suspicion)
The Endocrine Society guidelines for men with osteoporosis 2 and AACE/ACE guidelines 1 recommend additional testing when history or physical examination suggests specific causes:
- Thyroid-stimulating hormone (TSH) - if patient receives thyroid hormone or hyperthyroidism is suspected
- Total testosterone (in men) - to identify hypogonadism 2
- Celiac antibodies (tissue transglutaminase) - screens for celiac disease causing malabsorption
- Serum/urine protein electrophoresis - evaluates for multiple myeloma
Bone Turnover Markers: Limited Clinical Utility for Diagnosis
While bone turnover markers (BTMs) such as serum procollagen type 1 amino-terminal propeptide (PINP) for bone formation and β-C-terminal cross-linked telopeptide of type I collagen (β-CTX) for bone resorption are extensively studied 3, 4, 5, they cannot be used to diagnose osteoporosis due to low sensitivity and specificity 5.
When BTMs May Be Helpful
BTMs have three specific clinical applications:
- Patient evaluation: High values may indicate need to investigate secondary causes of osteoporosis 5
- Fracture risk prediction: Modest improvement in prediction with gradient of risk approximately 1.2 per SD increase, though this adds limited value beyond BMD and clinical risk factors 5
- Monitoring treatment adherence: The principal clinical utility is monitoring oral bisphosphonate therapy, where suppression of PINP and β-CTX greater than the least significant change indicates treatment adherence 5
Important Pitfalls to Avoid
Do not order BTMs for diagnosis - These markers have high biological and analytical variability and cannot establish or exclude osteoporosis 4, 5.
Ensure proper timing of 24-hour urine collection - Collecting urine calcium before vitamin D repletion and adequate dietary calcium intake will yield misleading results 1.
Consider secondary causes systematically - The high prevalence of secondary osteoporosis (40-85% in some series) means laboratory evaluation is cost-effective even in apparently healthy individuals 1.
Adjust testing based on clinical context - In men, testosterone measurement is essential 2. In patients with chronic kidney disease, standard BTMs may be unreliable and tartrate-resistant acid phosphatase 5b should be used instead of CTX 4.
The laboratory evaluation serves primarily to identify treatable secondary causes of osteoporosis rather than to diagnose osteoporosis itself, which remains a radiological diagnosis based on bone mineral density measurement by DXA.